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Abstract
Loss of Y-chromosome has been correlated with older age in males. Furthermore, current evidence indicates that Y-chromosome 
loss also occurs in several human tumors, including head and neck carcinomas. However, the association between Y nullisomy 
and the occurrence of neoplasias in elderly men has not been well established. In the present study, the association between 
Y-chromosome loss and head and neck carcinomas was evaluated by comparison to cells from peripheral blood lymphocytes 
and normal mucosa of cancer-free individuals matched for age using dual-color fluorescence in situ hybridization. Twenty-one 
patients ranging in age from 28 to 68 years were divided into five-year groups for comparison with 16 cancer-free individuals 
matched for age. The medical records of all patients were examined to obtain clinical and histopathological data. None of the 
patients had undergone radiotherapy or chemotherapy before surgery. In all groups, the frequency of Y-chromosome loss was 
higher among patients than among normal reference subjects (P < 0.0001) and was not age-dependent. These data suggest 
that Y-chromosome loss is a tumor-specific alteration not associated with advanced age in head and neck carcinomas. 
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Functional genes mapped to chromosome Y can be 
divided into three distinct groups. The first consists of 
identical genes on X- and Y-chromosomes located within 
the pseudoautosomal region, including those that play a 
role in metabolic pathways for cell energy and cell surface 
antigen expression. Recent evidence has suggested the 
presence of two miRNA mapped to the pseudoautosomal 
region (1). The second group has homologous but not 
identical genes on the X-chromosome. They are located in 
the non-recombinant region of the Y-chromosome (NRY) 
or male-specific Y-chromosome (MSY). The third group 
includes genes from the non-recombinant region such as 
SRY (sex-determining region Y). The pseudoautosomal 
regions present 19 coding genes and the euchromatic re-
gion of MSY has 78 genes (1). Although a small number of 
genes mapped to the Y-chromosome has been described, 
recent studies have demonstrated their involvement in sev-
eral diseases as well as in tumors affecting males such as 
gonadoblastomas (2) and prostate cancer (3). Therefore, 
the genes mapped to the Y-chromosome have the potential 
to influence cell proliferation and signaling transduction, 
or they can regulate gene expression by targeting specific 
mRNA. In general, Y-chromosome alterations show a great 
potential for involvement in human cancer (2). 
Earlier studies have shown that Y-chromosome loss 
is a normal phenomenon observed in the bone marrow of 
elderly males (4-6). Pierre and Hoagland (7) and Sakurai 
and Sandberg (8) suggested that, although Y-chromosome 
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loss should be recognized as a common age-related event, 
the percentage of Y loss is not dependent on age or dis-
ease. In 1992, the United Kingdom Cancer Cytogenetics 
Group (9) concluded that Y-chromosome loss in elderly 
males was not indicative of malignancy and should not be 
interpreted as a tumor marker. More recently, Zhang et al. 
(10) demonstrated that the frequency of Y-chromosome 
loss was significantly higher in patients with hematological 
disorders than in patients without such disorders, indicat-
ing that loss of the Y-chromosome is associated with a 
neoplastic process.
Current evidence indicates that Y-chromosome loss 
occurs in several human tumors, including prostate can-
cer (11-15), leukemia (16), esophageal carcinoma (17), 
gastric cancer (18), colorectal carcinoma (19), testicular 
germ cell tumor (2,20), renal carcinoma (21,22), as well 
as head and neck carcinomas (4). Recently, Singh et al. 
(23) demonstrated by large-scale epigenomic analysis 
the transcriptional potential of all protein-coding genes on 
the Y-chromosome including the SRY and the oncogene 
TSPY. According to the authors, the GBY locus may be 
hypomethylated in gonadoblastomas, resulting in overex-
pression of the TSPY and TTTY genes (24,25). However, 
the significance of Y-chromosome loss for the development 
or progression of these tumors is still unknown.
In head and neck carcinomas, Y-chromosome loss was 
initially detected by GTG-banding analysis (4,26). Using 
fluorescence in situ hybrization (FISH), Poetsch et al. (27) 
reported Y-chromosome loss in 53% of oropharyngeal, 
hypopharyngeal and laryngeal squamous cell carcinomas, 
except in poorly differentiated carcinomas. In laryngeal car-
cinomas, Szyfter et al. (28) found frequent Y-chromosome 
loss. Kujawski et al. (29) reported Y-chromosome loss as 
a common alteration in cell lines derived from primary and 
recurrent head and neck carcinomas, in primary larynx 
tumors and their corresponding metastases, and in multiple 
primary tumors from the same head and neck region.
In a previous study, our group reported Y-chromosome 
loss as the most frequent alteration in head and neck tumors 
analyzed by G-banding (27 of 59 cases). Fourteen of 27 
cases showed lymph node involvement and 15 of 27 died 
from the disease. These data suggested an association 
between Y nullisomy and poor clinical outcome (30). Based 
on these findings and on the evidence that Y-chromosome 
loss might be correlated with aging, we used a case-control 
study involving age-matched individuals in order to inves-
tigate this hypothesis. 
Material and Methods
Twenty-one samples of primary head and neck tumors 
were surgically removed and obtained from Hospital A.C. 
Camargo, São Paulo, Brazil (Table 1). The control sample 
consisted of 16 men randomly selected from the general 
population with no evidence of cancer or a family history 
of cancer matched for age with cases (ranging from 28 to 
68 years). Peripheral blood samples were collected from 
13 cases and a mucosa smear was obtained from three 
cases. The control individuals were not tobacco or alcohol 
consumers. Informed consent was obtained from all patients 
and controls prior to sampling. The Conselho Nacional de 
Ética em Pesquisa (CONEP #813/2000) approved this 
study. The medical records of all patients were examined 
to obtain clinical and histopathological data. First- and 
second-degree relatives with cancer were considered to 
be informative for family history. Whenever possible, the 
evidence for cancer was based on the medical records. 
None of the patients had undergone radiotherapy or che-
motherapy before surgery. Histopathological classification 
was based on the International Classification of Diseases 
for Oncology of the World Health Organization (WHO) (31). 
Clinical stage was determined using the TNM (tumor, lymph 
nodes, metastasis) Staging System (32).
Cytogenetic study
Twenty-one fresh tumor samples were obtained under 
sterile conditions and immediately processed. Chromosome 
preparation and cytogenetic analysis were carried out us-
ing standard techniques following the direct harvesting of 
primary cultures. Metaphase chromosomes were processed 
for GTG-banding (33). The karyotype description and the 
requirements for clonality were based on the International 
System for Human Cytogenetic Nomenclature (ISCN) (34). 
A further requirement for clonality was the presence of 
chromosomal alterations in at least two culture flasks. 
Normal cytogenetic controls were prepared from 
phytohemagglutinin-stimulated normal male lymphoblasts 
harvested for 72 h at 37°C, as described by Moorhead et 
al. (35).
Fluorescence in situ hybridization 
Suspension cells stored at -20°C were used for FISH. 
Hybridization, suppression hybridization, detection, fluores-
cence microscopy, and microphotography were performed 
as previously described (36). Briefly, the slides were dehy-
drated in ethanol (70, 85, and 100%) and air-dried. FISH 
was performed with a commercially available biotin-labeled 
centromeric probe for the Y-chromosome (LPE00YcG, 
Cytocell, UK) and a digoxigenin-labeled centromeric probe 
for chromosome 1 (LPE001R, Cytocell). Chromosome 1 
is one of the most stable in human tumors, since it is not 
frequently found altered in head and neck cancer (37). 
For hybridization, 10 µL of the probe was applied to each 
slide and denatured for 2 min at 75°C. Hybridization was 
performed for 1 h at 37°C in a dark chamber, after which 
the slides were rinsed in 0.25X SSC at 42°C followed by 
2X SSC/Tween 20 at room temperature.
On average, 341 interphase nuclei with intact morphol-
ogy, based on 4,6-diamino-2-phenylindole (DAPI) counter-
staining, were scored to determine the number of hybridiza-
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tion signals for the target probe and the frequencies of loss 
involving the Y-chromosome. A case was considered to have 
a numerical chromosome abnormality when the percentage 
of cells showing an abnormal number of hybridization signals 
was higher than the mean plus 2 standard deviations (2 SD) 
obtained for the same chromosome in the matched normal 
control. Image analysis was performed using an Olympus 
BX61 microscope connected to the FISHView EXPO 2.0 
software (Applied Spectral Imaging, USA). The guidelines 
used for FISH evaluation were those described by Hopman 
et al. (38). Slides were assessed in a blinded fashin by two 
observers (LCVC and NAB). Any discrepancy in sample 
classification was addressed by immediate review and the 
final result was reached by consensus. 
The Kruskal-Wallis or Mann-Whitney test was applied 
to compare Y loss frequencies between groups. Analysis 
of correlation between Y loss frequency and age was per-
formed using the Spearman rank test. 
Results
Twenty-one samples from male patients with head and 
neck carcinomas were investigated for Y-chromosome 
aneusomy in interphase nuclei. At least 100 interphase 
Table 1. Description of the 21 male patients studied according to age, histopathological diagnosis, TNM status, clinical data, and 
composite karyotype.
Patient Age 
(years)
Anatomic site Grade TNM Tobacco 
use
Alcohol 
use
Follow-up* 
(months)
Composite karyotype
 1 63 Floor of the mouth I T3N0M0 + - DOC (97) nd
 2 67 Glottic and infraglottic I T3N0M0 + + ANR (200) 47,XY,+2[3]
 3 58 Tongue II T3N1M0 + + DOC (94) nd
 4 39 Retromolar I T4N2aM0 + + DOD (15) 46,XY[5]
 5 60 Palate II T4N0M0 + - DOC (36) nd
 6 68 Tongue I T3N0M0 + + DOC (99) 40~46,X,-Y,-22[cp9]/46,XY[4]
 7 46 Floor of the mouth I T4N0M0 + + DOD (18) 44~49,X,-Y,del(5)(q15q23),+8,-9,-13,-19,
-21,+22,+mar[cp10]/46,XY[10]
 8 58 Gingiva II T4N0M0 + + DOD (52) 46,XY[7]
 9 63 Retromolar I T4N1M0 + + DOD (81.8) nd
10 66 Floor of the mouth I T4N0M0 + + DOC (2d ) 41~45,X,-Y,+17,-20,+mar[cp19]/46,XY[5]
11 35 Tongue II T4N0M0 - + DOD (6) 43~48,XY,-9,+10,-17,+22[cp15]/46,XY [21]
12 40 Tongue IV T4N2M0 + + DOD (31) 44~48,X,-Y,+10,+20,+22[cp10]/46,XY[17]
13 63 Oropharynx I T4N0M0 + + DOD (15) 41~48,X,-Y,+9,add(9)(p24),+13,-18,-19,
+22[cp21]/46,XY[8]
14 64 Epiglottic II T3N0M0 + + ANR (183) 44~48,X,-Y,+7,-10,-21,+22,+del(22)
(q13.1)[7][cp20]/46,XY[9]
15 62 Tonsil II T4N2M0 + + DOD (8) 42~47,X,-Y,-3,-15,+15,-17,-19,-22 
[cp17]/46,XY[17]
16 63 Floor of the mouth II T2N0M0 - - DOD (126) 42~48,X,-Y,-3,-9,-14,-16,-18,-19,+22,
+mar[cp16]/46,XY[9]
17 65 Retromolar II T4N2bM0 + + DOD (94) 43~47,X,-Y,del(1)(q21),-9,-10,inv(12) 
(p13.3q12),-17,-18,-21,+22,
+mar[cp21]/46,XY [17]
18 57 Epiglottic I T3N2cM0 + + DOC (21) 41~48,X,-Y,-4,+6,+del(6)(q22),-11,-12,
-15,-16,-19,-22,+?del(22)(q13.1),
+mar[cp18]/46,XY[6]
19 56 Tonsil II T3N2cM0 + + ANR (183) 44~47,X,-Y,+7,-19,-20,+22,+mar[cp17]/
46,XY[1]
20 65 Larynx/transglottic I T4N0M0 + + ANR (182) 44~49,XY,del(1)(q41),?add(4q),+20, 
del(22)(q13.1),+mar[cp11]/46,XY[13]
21 32 Maxillary antrum III T4N2M0 - + DOD (20) 43~47,-X,-Y,del(6)(q21q23),+10,
+22[cp11]/46,XY[6]
*Months from surgery to July 2011. TNM = tumor, lymph nodes, metastasis; (-) = negative history; (+) = positive history; d = days; DOC 
= died from other causes; DOD = died of disease; ANR = alive with no recurrence; nd = not determined. 
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nuclei were analyzed, except in three 
cases (samples 12, 14, and 15). A high 
frequency of Y-chromosome loss was 
observed, ranging from 11 to 85% (Table 
2, Figures 1A,B and 2). Considering a 
cut-off rate of 25% as significant, Y-
chromosome loss was detected in 18 
of the 21 cases analyzed. 
G-banding results were previously 
obtained in 17 cases (33), 12 of whom 
presented Y-chromosome loss as part 
of a more complex abnormal karyotype 
(Table 1). FISH analysis confirmed Y 
loss in all cases previously studied by G-
banding, although 14 cases showed the 
alteration in more than 25% of cells. 
To investigate the association 
between Y-chromosome loss and ad-
vanced age, 13 samples from normal 
individuals matched for age with the 
cases were evaluated. Y-chromosome 
loss was observed in 1 to 23% of the 
reference cells (Table 2). The normal 
mucosa from 3 healthy individuals 
revealed losses ranging from 14.7 to 
30.8% of cells. When cases and the 
reference group were compared by age 
in periods of 5 years, a higher frequency 
of Y-chromosome loss was detected in 
head and neck patients compared to 
reference cases. 
Tumor cases showed statistically 
higher frequencies of Y loss compared 
to control and buccal smear controls 
(P < 0.0001). Y-chromosome loss was 
more frequently detected in tumors 
than in peripheral blood samples from 
controls (P < 0.0001) and buccal smear 
from healthy individuals (P = 0.0359; 
Figure 1A). No correlation was observed 
between age and Y-chromosome loss 
frequency in controls (peripheral blood 
and buccal smear) and tumor cases (P 
= 0.1090, r = 0.4160, and P = 0.3398, r 
= 0.2192, respectively, Spearman test; 
Figure 1B).
Discussion
Abnormal karyotypes have been 
reported in about 400 primary head and 
neck squamous cell carcinomas includ-
ing clonal loss of the Y-chromosome 
(37). Although the significance of this 
alteration in the biology of the disease 
Table 2. Loss of Y-chromosome by head and neck cancer patients and controls grouped 
by age using FISH analysis.
Age groups Age (years) Case No. Y loss/total No. cells Frequency (%)
28-32 years 32 Case 21 31/184 17
28 Control 1 5/534 1
31 Control 2 71/307 23
Control 1+2 76/841 9
28 Smear 1 22/149 15
33-37 years 35 Case 11 48/101 47
37 Control 3 84/684 12
38-42 years 39 Case 4 102/199 51
40 Case 12 52/93 56
39 Control 4 64/467 14
41 Smear 2 25/153 16
43-47 years 46 Case 7 147/674 22
46 Control 5 51/667 8
53-57 years 56 Case 19 55/216 25
57 Case 18 219/784 28
57 Control 6 42/529 8
58-62 years 58 Case 3 73/119 61
58 Case 8 350/411 85
60 Case 5 160/275 58
62 Case 15 25/57 44
59 Control 7 85/590 14
64 Control 8 82/593 14
Control 7 + 8    167/1183 14
63-67 years 63 Case 13 40/296 13
63 Case 16 38/100 38
63 Case 9 41/312 13
64 Case 14 16/44 36
65 Case 17 97/235 41
65 Case 10 58/100 58
66 Case 1 292/500 58
66 Case 10 105/123 85
67 Case 2 34/134 25
64 Control 9 88/593 15
65 Control 10 16/525 3
68 Control 11 72/450 16
Control 9+10+11       176/1568 11
68-72 years 68 Case 6 137/232 59
68 Control 12 93/593 16
68 Control 13 103/450 23
Control 12+13 196/1043 19
72 Smear 3 29/159 18
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has remained elusive, recent studies have demonstrated 
that translation repression or mRNA degradation might 
also occur on the Y-chromosome. Recently two microRNAs 
(small RNAs that regulate gene expression) were identified 
on chromosomes X and Y (1). In an epigenetic profile of 
the euchromatic region of the human Y-chromosome, Singh 
et al. (23) observed in white blood cells that genes TSPY 
and TTTY mapped to the Y-chromosome appeared to be 
silenced by DNA methylation mechanisms. It is interesting 
to note that loss of methylation at this DNA locus has been 
Figure 1. A, Y loss frequency in tumor cases, peripheral blood and buccal smear from controls. The Kruskal-Wallis or Mann-Whitney 
test was applied to compare the frequency of Y-chromosome loss between groups. B, Correlation analysis between age and frequency 
of Y-chromosome loss in tumor cases (P = 0.3398, r = 0.2192) and controls (P = 0.1090, r = 0.4160) was performed using the Spear-
man rank test.
Figure 2. A, G-banded metaphase from a squamous cell carcinoma (case 14) with a 44,X,-Y,+7,-16 karyotype. B, Interphase normal 
cell (peripheral lymphocyte) with two red signals (chromosome 1), one green signal (Y-chromosome) and one tumor nucleus showing 
loss of the Y-chromosome. 
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observed in the promoters of oncogenes in cancer. These 
results revealed that genes mapped to the Y-chromosome 
could be considered as potential molecular markers in 
cancers.
In the present study, using dual-color FISH, it was 
demonstrated that Y-chromosome loss is age-independent 
and is a frequent chromosomal alteration in head and neck 
squamous cell carcinomas. As expected, older patients 
(>50 years old) were the most affected by the disease (17 
of 21 male patients). All cases presented Y aneusomy; 
however, in two younger patients (7 and 21) and in two 
older patients (9 and 13) this alteration was non-significant 
(cut-off of 25% as significant). Four patients of this study 
were alive without recurrence after a follow-up ranging 
from 182 to 200 months; all of them were older (>50 years 
old) and presented a significant loss of the Y-chromosome. 
Previously, in a large series of head and neck carcinomas 
evaluated by GTG-banding, loss of Y-chromosome was 
detected in 26 of 58 (45%) head and neck carcinomas, 24 
of which were T3-T4; 14 of 26 cases showed involvement 
of the lymph nodes and 16 of 26 died of the disease (30). 
Five patients aged <50 years showed loss of Y-chromosome; 
4 of them were in stage T4 and two died of the disease. 
Although these data were not statistically significant, the 
authors showed a suggestive association between loss 
of the Y-chromosome and a poor outcome (30). Similarly, 
Kujawski et al. (29) were unable to find any correlation 
between Y-chromosome loss and disease progression and 
aggressiveness in head and neck carcinomas. However, 
the number of cases studied here is small for conclusions 
regarding the prognosis.
In addition, it was shown that the frequency of cells with 
Y loss did not increase with age and was significantly higher 
in cases than in cancer-free individuals matched for age. 
These data suggest that Y aneusomy is an event related to 
the disease. Regarding hematologic diseases, Wiktor et al. 
(6) reported an investigation of 185 male patients and 30 
normal controls (aged 45-97 years) with Y loss as the only 
cytogenetic abnormality. They showed that Y loss was signifi-
cantly greater in cases, with only 10% of the controls showing 
a >75% loss compared to 29% for those with disease.
In contrast, Jin et al. (26) reported that Y loss increased 
with advanced age in non-neoplastic upper aerodigestive 
tract mucosa. No Y-chromosome losses were detected in 
15 samples from men aged more than 40 years, whereas 
70% of the samples from men aged 60-79 years displayed 
clonal loss of chromosome Y. However, none of the samples 
analyzed were subjected to histopathological analysis. In 
the present study, Y-chromosome loss was not correlated 
with aging in peripheral blood cells or in normal mucosa 
from healthy individuals.
It has been suggested that chromosome Y has a tumor 
suppressor gene, the loss of which plays a role in the early 
steps of tumor development (39). Genes located on the Y-
chromosome appear to be involved in cell cycle regulation, 
signal transduction, cellular growth, and protein degradation 
(40), as well as in the regulation of gene expression (1). 
Mutations involving these genes could lead to carcinogen-
esis (2). Vijayakumar et al. (15) used a PC-3 cell line, which 
shows Y aneusomy, to evaluate the effect of the addition 
of chromosome Y on the prostate tumorigenic phenotype 
in prostate cancer cells. The authors found tumorigenicity 
suppression suggesting the presence of a tumor suppressor 
gene mapped to the Y-chromosome. 
The present findings suggest the involvement of the 
Y-chromosome as a tumor-associated abnormality not re-
lated to age at the onset of head and neck cancer. Recent 
literature findings demonstrating that genes mapped to the 
Y-chromosome may act as regulators of gene expression 
as well as being controlled by epigenetic events make this 
chromosome an interesting target for the study of tumor 
markers.
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